Show simple item record

dc.contributor.authorBanerjee, S.
dc.contributor.authorGrochot, R.
dc.contributor.authorShinde, R.
dc.contributor.authorLima, J.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorRahman, Rozana A
dc.contributor.authorLittle, Martin
dc.contributor.authorTunariu, N.
dc.contributor.authorCurcean, A.
dc.contributor.authorBadham, H.
dc.contributor.authorMahmud, M.
dc.contributor.authorTurner, A.
dc.contributor.authorParmar, M.
dc.contributor.authorYap, C.
dc.contributor.authorMinchom, A.
dc.contributor.authorLopez, J.
dc.contributor.authorde Bono, J.
dc.contributor.authorBanerji, U.
dc.date.accessioned2021-10-28T09:26:14Z
dc.date.available2021-10-28T09:26:14Z
dc.date.issued2021en
dc.identifier.citationBanerjee S, Grochot R, Shinde R, Lima J, Krebs M, Rahman R, et al. 725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S728.en
dc.identifier.doi10.1016/j.annonc.2021.08.1168en
dc.identifier.urihttp://hdl.handle.net/10541/624713
dc.description.abstractBackground Patients with low grade serous ovarian cancer (LGSOC) have limited response to conventional chemotherapy and hormonal therapy. Recently, MEK inhibitors have shown an overall response rate (ORR) 15-26%. Activation of p-FAK is a possible mechanism of resistance to MEK inhibitors and we hypothesised combination of a RAF/MEK inhibitor with a FAK inhibitor would overcome this. Methods We explored the safety, pharmacokinetics and pharmacodynamics in the dose escalation study and recommended a phase two dose of the combination of RAF/MEK inhibitor VS-6766 3.2 mg twice a week and the FAK inhibitor defactinib 200 mg twice daily, both administered 3 out of 4 weeks in 28 day cycles in a highly intermittent dosing schedule. We evaluated confirmed responses using RECIST 1.1. We present the efficacy of the combination in patients with LGSOC in this trial so far. Results Currently, 25 patients with LGSOC have been treated with 24 evaluated for response, median age 57 (range 31 to 75 years) and median previous lines of therapy 4 (range 1 to 9). Of the 24 evaluable patients, 11 (46%) had KRAS mutations and 10 (42%) received prior MEK inhibitor treatment. The most common adverse events were rash and CK elevation which were predominantly grade 1/2. The overall response rate in all patients was 46% (11/24, 95% CI: 28% to 65%), with ORR of 64% (7/11, 95% CI: 35% to 85%) in patients with KRAS mutations, and 44% (4/9, 95% CI: 19% to 73%) in patients with KRAS wildtype tumours. Four patients had undocumented KRAS status. Responses were observed in patients with and without prior MEK inhibitor treatment. The median progression free survival was 23 months for the whole cohort, 13/24 patients are still on study and updated results will be presented. Conclusions An intermittent dosing schedule of the combination of VS-6766 and defactinib has shown encouraging clinical activity in patients with recurrent LGSOC. These data support an ongoing registration-directed study of VS-6766 � defactinib in patients with recurrent LGSOC (ENGOT-ov60/NCRI/GOG-3052; NCT04625270).en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2021.08.1168en
dc.titlePhase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian canceren
dc.typeOtheren
dc.contributor.departmentGynaecology Unit, The Royal Marsden NHS Foundation Trust, Sutton, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2021-11-03T10:04:05Z


Files in this item

Thumbnail
Name:
AnnOncBanerjee.pdf
Size:
73.52Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record